Esophageal Implant for Esophageal Reconstruction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new esophageal implant called the Cellspan™ Esophageal Implant (CEI), which combines a synthetic scaffold with a person's own stem cells to help regrow a damaged esophagus. It is designed for individuals needing a section of their esophagus rebuilt, particularly those with stubborn esophageal narrowing or holes that have not improved after other treatments. Ideal candidates for this trial are those who have had at least three different treatments fail and require surgery to repair a short part of their esophagus. The trial aims to determine if this implant can safely and effectively aid in healing the esophagus and restoring its function. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What prior data suggests that the Cellspan™ Esophageal Implant is safe for esophageal reconstruction?
Research has shown that the Cellspan™ Esophageal Implant (CEI) is still undergoing safety testing in humans. Earlier studies found that similar esophageal grafts can be successfully used for esophageal reconstruction in people. However, since this is the first human trial for the CEI, information on patient tolerance and potential side effects remains limited.
An independent Data Monitoring Committee closely monitors this trial to ensure safety. They use a step-by-step approach to enroll participants, carefully reviewing each case before proceeding. This process helps identify and address any safety issues quickly. While the study aims to determine the safety of the CEI, the absence of previous human trials means potential participants should be aware of the uncertainties involved.12345Why do researchers think this study treatment might be promising?
Most treatments for esophageal reconstruction involve complex surgeries or grafts using tissue from other parts of the body, which can be invasive and come with significant recovery time. The Cellspan™ Esophageal Implant (CEI) is unique because it offers a potentially less invasive alternative that uses a synthetic scaffold to encourage the body's own cells to regenerate the esophagus. This innovative approach not only reduces the need for extensive surgery but also aims to improve healing by harnessing the body's natural regenerative processes. Researchers are excited about this treatment because it could lead to quicker recovery times and fewer complications, revolutionizing how we approach esophageal reconstruction.
What evidence suggests that the Cellspan™ Esophageal Implant is effective for esophageal reconstruction?
Research has shown that the Cellspan™ Esophageal Implant (CEI), which participants in this trial will receive, has yielded promising results in animal studies. In pigs, the implant facilitated tissue regrowth after esophagus removal, forming a new, continuous tube-like structure. Early findings also suggest that mesenchymal stem cells can repair the esophagus rapidly, in about two weeks. Although data on humans is limited, these results provide a strong basis for expecting similar outcomes in people.12356
Are You a Good Fit for This Trial?
This trial is for adults over 18 who've tried at least three treatments without success for esophageal conditions like strictures, perforations, or fistulas. They must need and be able to undergo a short segment esophageal reconstruction within the thoracic cavity and be considered high-risk for standard procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Implantation and Initial Monitoring
Participants undergo the CELLSPAN Esophageal Implant procedure and are monitored for immediate post-surgical outcomes
Follow-up
Participants are monitored for safety and effectiveness after treatment, including imaging and endoscopic evaluations
Long-term Follow-up
Participants are followed for a minimum of 2 years post-implant surgery to assess long-term safety and efficacy
What Are the Treatments Tested in This Trial?
Interventions
- Cellspan™ Esophageal Implant (CEI)
Cellspan™ Esophageal Implant (CEI) is already approved in United States, European Union for the following indications:
- Short segment esophageal replacement
- Refractory benign esophageal strictures (RBES)
- Esophageal perforation
- Chronic/persistent esophageal fistula
- Orphan designation for esophageal reconstruction
Find a Clinic Near You
Who Is Running the Clinical Trial?
Biostage, Inc.
Lead Sponsor
Harvard Apparatus Regenerative Technology, Inc.
Lead Sponsor